Richmond, Va.
Thursday, Nov. 27, 2014

VCU physicist, collaborator receive $2 million grant to improve melanoma treatment

Monday, June 16, 2014

Jason Reed, Ph.D., an assistant professor at Virginia Commonwealth University, has been awarded a roughly $2 million grant with a collaborator at the University of California, Los Angeles, to develop a new method to rapidly determine how a cancerous tumor responds to a battery of candidate therapies and then to pick the agents that are most effective for treating the patient’s particular disease.

Reed, who works in the Department of Physics in VCU's College of Humanities and Sciences and is a research member at VCU Massey Cancer Center, and UCLA's Michael Teitell, M.D., Ph.D., received the four-year grant from the National Cancer Institute at the National Institutes of Health. Approximately $1 million of the grant will go to research conducted at VCU.

The researchers received the grant to find an answer to one of the National Cancer Institute's key priorities: "Since current methods to predict the efficacy or toxicity of new drug candidates in humans are often inaccurate, can we develop new methods to test potential therapeutic agents that yield better predictions of response?"

Reed and Teitell proposed to develop a new, rapid, high-throughput, real-time, generic drug response quantifier, called Live Cell Interferometry (LCI), on an open platform configuration to handle issues of tissue and growth heterogeneity that typically accompany all tumor types.

LCI, Reed said, will determine therapeutic sensitivity of melanoma cells by tracking single cell biomass changes (growth and wasting) over time, before and after drug exposure, to avoid confounding artifacts of current, static, snapshot-in-time therapy selection methods.

He added that it will directly address key challenges such as mortality associated with metastasis, identifying hard to treat versus relatively indolent tumors, identifying hard to treat versus relatively indolent tumors, tailoring therapies to improve efficacy, reducing toxicity, and uncovering new growth and metastasis mechanisms.

About VCU and VCU Medical Center

Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 223 degree and certificate programs in the arts, sciences and humanities. Sixty-eight of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University comprise VCU Medical Center, one of the nation’s leading academic medical centers. For more, see www.vcu.edu.

About the VCU Massey Cancer Center

VCU Massey Cancer Center is one of only 68 National Cancer Institute-designated institutions in the country that leads and shapes America’s cancer research efforts. Working with all kinds of cancers, Massey conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers the most cancer clinical trials in Virginia and serves patients at 10 locations. Its 1,000-plus researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately cure cancer. Visit Massey online at www.massey.vcu.edu or call 877-4-MASSEY for more information.
VCU Massey Cancer Center
Jason Reed, Ph.D.